Cholecystokinin-8 vs BYM338
Head-to-head comparison of Cholecystokinin-8 (Cholecystokinin (sulfated C-terminal octapeptide, CCK-8)) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cholecystokinin-8 | BYM338 |
|---|---|---|
| Category | Endocrine Peptides | Muscle & Performance |
| Full Name | Cholecystokinin (sulfated C-terminal octapeptide, CCK-8) | Bimagrumab (BYM338) |
| Molecular Weight | 1143.2 Da | ~148 kDa |
| Half-Life | 1-2 min | ~2-3 weeks |
| Amino Acids | DY(SO3H)MGWMDF-NH2 | N/A |
| Typical Dose | physiologic low-picomolar-nanomolar range|research-dependent | 10-30 mg/kg IV in trials |
| Route | endogenous secretion|research IV/SC | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 97 | 140 |
| Research Status | Endogenous | Clinical |
Cholecystokinin-8 Benefits
- ✓gallbladder contraction
- ✓pancreatic enzyme release
- ✓satiety signaling
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Cholecystokinin-8 Dosing
physiologic secretion|research-dependent
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Cholecystokinin-8 Side Effects
- ⚠abdominal cramping
- ⚠nausea
- ⚠biliary contraction
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
Cholecystokinin-8
CCK-8 is a canonical gut hormone fragment with extensive documentation in digestive physiology and appetite control. Sulfation of the tyrosine residue is important for high-affinity receptor activity.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.